Any idea which company $.75/share that has the anti-cancer patent being pitched by the Oxford Group? Claims FDA announcement imminent within the next 90 days and the stock expected to explode by 6263%Pot Stock under $1 set to explode by 6263% because it has anti-cancer breakthrough results FDA announcement imminent within the next 90 days being pitched by The Oxford Group. Any idea which pot stock this one is?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Is this the same as Jimmy Mengle is preaching?
Yes. Any ideas which company?
Yes, this appears to be the same Company Jimmy Mengel is teasing. ,,,My research found out that Dr. Stephen Wright is one of the three persons that Jimmy Mengel alludes to in his teaser: Stephen Wright was the R&D Director for GW in 2004, he had worked for Ispen as Senior VP of Cinical R&D, and was the Medical Director of Immuno sciences at Abbott Labs.
So that’s a perfect fit. I just can’t find what company he’s currently with. He’s on Linked-In but not responding to my messaging. Identifying the other two company members Mengel talks about (CEO and one other) and finding their company will get the answer. I haven’t seen the Oxford groups teaser so there may be additional clues there.
I’m beginning to feel more like a sleuth, rather than an investor. I came up with Dr. wright on a discussions page on Google as well. The tie-in on GW and Abbot and Glaxo provided the “Good Doctor.” Now, who are the recent lab rats he’s conferring with? Yes, I know, ending on a preposition. I could use an explosion on my portfolio.
If somebody can post the Oxford group teaser we can get some clues.
We were thinking InMed Pharmaceuticals, Inc. (IMLFF)??
INMED is what I thought it was as well.
Bingo. I think you nailed it with INMED. Thanks
Appears to be INMED. My only concern is their website and last press release in May 2018 doesn’t mention anything about them working on cancer or breast cancer, so Jimmy Mengel’s claims regarding that are a bit suspicious.
I found a Canadian company called Hysaynth who has the technology for the cancer drug . One founderis Kevin Chen
Thanks, Earl.
Is there a tie back to the other description point from the Oxford teaser?
I don’t see this as Hyasynth as they are a private complamy not traded. All the clues leed to InMed Pharma. A look at some more clues from Jimmie Mengel: “The last member of this team is the chief scientific officer, he spent 20 years in drug discovery and development….he’s authored more than 40 peer-review papers”.
Here is the write up on the InMed website:
Dr. Sazzad Hossain, Ph.D., M.Sc.
Chief Scientific Officer
Dr. Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development…..He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.”
So that’s a perfect fit. I’ve read through InMed Website and nowhere do they mention and Project or active research on “Breast Cancer” or even “Cancer” for that matter. It seems if a company was working on Breast Cancer” they would want the investors to know that.
So we are left to believe all the marketing idiots posting this teaser that the InMed CEO has privately told Jimmy Mengel that they are “On the brink of announcing a “$1 Billion deal with the FDA. And it will share the details of brand-new clinical trials for it’s first drug targeting defective protiens” While no one else knows about this, not even InMeds investors, somehow Jimmy Mengel knows.
The real validation of FDA fast track approval for InMeds breast cancer cure would be researching what’s been submitted to/under review by the FDA Though I don’t know how to go about that.
InMed CEO Eric Adams reveals info about their work with breast cancer on an interview with James West / MidasLetter, April of 2017. Right out of his own mouth.
May be BLCM. bellicum.com
A friend bought a subscription to Jimmie Mengel’s publication regarding this issue. The company was NOT revealed in the subscription, (pretty lame to tease a stock and then not reveal it to subscribers). My friend called the Oxford Club to cancel his subscription because the teaser stock had not been revealed. They gave him the name of the stock to keep him from canceling. The Oxford Club Staff advised that the stock is, in fact, InMed Therapeutics. IMLFF.
Love your reviews and your detective work on all those scams,promises and fake news.
GUMSHOE RULES!